MedTrace Logo

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

NCT05935098 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2026-03-13

No results posted yet for this study

Summary

This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic solid tumors.

Key details of the study include:

* The study is expected to last about 36 months.
* Participants will receive treatment until they either no longer benefit from the treatment, experience side effects that are too severe, or choose to stop participating.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Solid Tumor

Interventions

DRUG

Tislelizumab

Administered intravenously

DRUG

Chemotherapy

Administered in accordance with relevant local guidelines and/or prescribing information.

DRUG

BGB-A3055

Administered intravenously

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2026-01-27
Completion
2026-01-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • France
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05935098 on ClinicalTrials.gov